NO940778L - Mutant growth factor receptor as a drug and its use to treat cancer - Google Patents

Mutant growth factor receptor as a drug and its use to treat cancer

Info

Publication number
NO940778L
NO940778L NO940778A NO940778A NO940778L NO 940778 L NO940778 L NO 940778L NO 940778 A NO940778 A NO 940778A NO 940778 A NO940778 A NO 940778A NO 940778 L NO940778 L NO 940778L
Authority
NO
Norway
Prior art keywords
growth factor
treatment
cancer
drug
receptor
Prior art date
Application number
NO940778A
Other languages
Norwegian (no)
Other versions
NO940778D0 (en
Inventor
Norbert Redemann
Axel Ulrich
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of NO940778D0 publication Critical patent/NO940778D0/en
Publication of NO940778L publication Critical patent/NO940778L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Muterte reseptortyrosinkinaser er nyttige som medika- menter. Disse muterte vekstfaktorreseptorer er særlig fordelaktige for behandling av kreftsykdommer, spe- sielt av de krefttyper hvor overaktiviteten av vekst- faktorreseptorer spiller en rolle ved kreftdannelsen, samt for behandling av andre sykdommer forårsaket av reseptoroveraktivitet. Mutanter av EGF- reseptorene hvori tyrosinkinaseaktiviteten av villtype- reseptoren er eliminert ved punktmutasjon eller dele- sjon i tyrosinkinasedomenet, er særlig effektive me- dikamenter for behandling av kreft.Mutated receptor tyrosine kinases are useful as drugs. These mutated growth factor receptors are particularly advantageous for the treatment of cancer diseases, especially of those cancers in which the overactivity of growth factor receptors plays a role in cancer formation, and for the treatment of other diseases caused by receptor overactivity. Mutants of the EGF receptors in which the tyrosine kinase activity of the wild-type receptor is eliminated by point mutation or deletion in the tyrosine kinase domain are particularly effective drugs for the treatment of cancer.

NO940778A 1991-09-05 1994-03-04 Mutant growth factor receptor as a drug and its use to treat cancer NO940778L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19914129533 DE4129533A1 (en) 1991-09-05 1991-09-05 MUTTED GROWTH FACTOR RECEPTOR AS A MEDICINAL PRODUCT AND ITS USE FOR TREATING CANCER
PCT/EP1992/002058 WO1993005148A1 (en) 1991-09-05 1992-09-07 Mutated growth factor receptor as medicament and its use for treating cancer

Publications (2)

Publication Number Publication Date
NO940778D0 NO940778D0 (en) 1994-03-04
NO940778L true NO940778L (en) 1994-05-04

Family

ID=6439926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940778A NO940778L (en) 1991-09-05 1994-03-04 Mutant growth factor receptor as a drug and its use to treat cancer

Country Status (12)

Country Link
EP (1) EP0667899A1 (en)
JP (1) JPH07502884A (en)
CN (1) CN1071586A (en)
AU (1) AU669857B2 (en)
CA (1) CA2117073A1 (en)
DE (1) DE4129533A1 (en)
FI (1) FI941053A (en)
MX (1) MX9205084A (en)
NO (1) NO940778L (en)
NZ (1) NZ244239A (en)
PT (1) PT100844A (en)
WO (1) WO1993005148A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465623B2 (en) 1995-05-02 2002-10-15 Garvan Institute Of Medical Research GDU, a novel signalling protein
AUPN274295A0 (en) * 1995-05-02 1995-05-25 Garvan Institute Of Medical Research GDU, a novel signalling protein
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
ES2741547T3 (en) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Method to determine the response of cancer to treatments directed at the epidermal growth factor receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762623A1 (en) * 1988-01-22 2007-03-14 ZymoGenetics, Inc. Methods for producing biologically active peptide dimers
WO1990008160A1 (en) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Growth factor receptor-like peptides without tyrosine-kinase activity
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
JP2975679B2 (en) * 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ Structural change of EGF receptor gene in human glioma

Also Published As

Publication number Publication date
FI941053A0 (en) 1994-03-04
NO940778D0 (en) 1994-03-04
AU669857B2 (en) 1996-06-27
FI941053A (en) 1994-04-08
JPH07502884A (en) 1995-03-30
MX9205084A (en) 1993-05-01
PT100844A (en) 1994-05-31
EP0667899A1 (en) 1995-08-23
CN1071586A (en) 1993-05-05
CA2117073A1 (en) 1993-03-18
AU2518592A (en) 1993-04-05
WO1993005148A1 (en) 1993-03-18
NZ244239A (en) 1995-07-26
DE4129533A1 (en) 1993-03-11

Similar Documents

Publication Publication Date Title
WO1995024190A3 (en) Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
ATE331514T1 (en) INDOLINONE DERIVATIVES FOR ALTERING C-KIT TYROSINE PROTEIN KINASE
JO2319B1 (en) Indazole compounds and pharmaceutical compositions and methods for their use
NO20021166L (en) Tyrosine kinase inhibitors
MXPA06001193A (en) 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation.
MY128370A (en) Pyrrolotriazane inhibitors of kinases
GB9323165D0 (en) Compounds
HUP0002084A2 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases and pharmaceutical compositions containing them
DE69631423D1 (en) CHINOLONES AND THEIR THERAPEUTIC USE
AU2911489A (en) Quinoline derivatives as antagonists of leukotriene d4
NO20002121L (en) Benzothiazol-protein-tyrosine kinase inhibitors
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
DK0909315T3 (en) CCK-2, a receptor tyrosine kinase
NO20053486L (en) 2- (1H-indazol-6-ylamine) -benzamide compounds as protein kinase inhibitors useful in the treatment of ophthalmic diseases
GB9806739D0 (en) Cyclin dependent kinase inhibitors
NO940778L (en) Mutant growth factor receptor as a drug and its use to treat cancer
NO992187L (en) Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods for its use
Huwiler et al. Stimulation by extracellular ATP and UTP of the stress‐activated protein kinase cascade in rat renal mesangial cells
MX9304801A (en) 2-thioindoles and related disulfides which inhibit protein tyrosine kinases and which have antitumor properties.
TR199700956T1 (en) Indazole carboxamides.
Gangopadhyay et al. Carcinoembryonic antigen induces signal transduction in Kupffer cells
ATE143808T1 (en) PROTEIN TYROSINE PHOSPHATASE ALPHA - INHIBITORS FOR TUMOR TREATMENT
Burns et al. Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites
Manzow et al. Evidence against a role of general protein kinase C downregulation in skin tumor promotion
HUT54494A (en) Process for producing pharmaceutical compositions comprising buspirone and its salts